论文部分内容阅读
目的:研究老年肺结核新型化疗方案疗效及对肝脏的近期损害。方法:2011年6月-2013年6月收治肺结核疾病患者76例,随机分为试验组和对照组,各38例。对照组实行抗结核板式组合药物等进行治疗;试验组实行将两种以上抗结核药按一定的剂量制成的抗结核固定复合制剂(以下简称FDC)进行化疗治疗。结果:在完成整个治疗后,试验组的痰菌转阴率92%,对照组75%。两组比较差异具有统计学意义(P<0.05)。试验组有2例患者出现肝脏损害,对照组有4例患者出现肝脏损害。对所有患者进行相关的肝脏损害治疗后,患者的转氨酶均得到了有效控制。结论:FDC新型化疗方案治疗老年肺结核具有良好的治疗效果,搭配治疗可以减轻患者在化疗中产生的不良反应,更加安全可靠,同时也具有良好的耐受性,值得在实际临床中推广。
Objective: To study the efficacy of the new chemotherapy regimen in elderly patients with pulmonary tuberculosis and the recent damage to the liver. Methods: From June 2011 to June 2013, 76 patients with pulmonary tuberculosis were randomly divided into experimental group and control group, with 38 cases in each group. The control group was treated with antituberculosis drugs such as plate combination. The experimental group was given chemotherapy for anti-tuberculosis fixed composite (hereinafter referred to as FDC) made by two or more kinds of anti-TB drugs according to a certain dosage. Results: After the whole treatment was completed, the rate of sputum negative conversion in the test group was 92% and in the control group 75%. The difference between the two groups was statistically significant (P <0.05). Liver damage was observed in 2 patients in the test group and liver damage in 4 patients in the control group. In all patients for liver damage treatment, the patient’s aminotransferases have been effectively controlled. Conclusion: The new chemotherapy regimen of FDC has a good therapeutic effect in the treatment of senile pulmonary tuberculosis. With the treatment, it can reduce the side effects of chemotherapy in patients with chemotherapy, is more safe and reliable, and has good tolerance. It is worth to be popularized in clinical practice.